PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

Phase 2

Completed

Conditions: Lyme Borreliosis

Interventions: Biological: VLA15
Biological: Placebo

First Posted Date: 2019-05-31

Last Posted Date: 2023-04-21

Lead Sponsor: Pfizer

Target Recruit Count: 246

Registration Number: NCT03970733

Locations: 🇺🇸
Clinical Research Consulting, LLC, Milford, Connecticut, United States
🇺🇸
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸
United Medical Associates, Binghamton, New York, United States

and more 2 locations

A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Non-alcoholic Steatohepatitis

Interventions: Drug: PF-06835919
Drug: Placebo

First Posted Date: 2019-05-31

Last Posted Date: 2022-05-11

Lead Sponsor: Pfizer

Target Recruit Count: 164

Registration Number: NCT03969719

Locations: 🇨🇦
The Western Centre for Functional and Metabolic Mapping, London, Ontario, Canada
🇺🇸
Hope Clinical Research, Canoga Park, California, United States
🇺🇸
eStudySite, La Mesa, California, United States

and more 101 locations

Comparative Analysis of Outcomes Among Patients Treated With Xeljanz vs Biologics

Completed

Conditions: Arthritis, Rheumatoid

First Posted Date: 2019-05-28

Last Posted Date: 2021-06-02

Lead Sponsor: Pfizer

Target Recruit Count: 7308

Registration Number: NCT03964649

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Phase 2

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: PF-06700841
Other: Placebo

First Posted Date: 2019-05-24

Last Posted Date: 2021-08-04

Lead Sponsor: Pfizer

Target Recruit Count: 219

Registration Number: NCT03963401

Locations: 🇵🇱
RCMed Oddzial Sochaczew, Sochaczew, Poland
🇵🇱
Zespol Poradni Specjalistycznych "REUMED" Filia nr 2, Lublin, Poland
🇦🇺
Emeritus Research, Melbourne, Victoria, Australia

and more 45 locations

Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants

Phase 1

Completed

Conditions: Adult
Drug Interactions
Healthy Volunteers
Humans

Interventions: Drug: Lorlatinib 100 mg
Drug: Lorlatinib 50 mg
Drug: Lorlatinib 75 mg

First Posted Date: 2019-05-23

Last Posted Date: 2020-01-18

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT03961997

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Be-bru, Belgium

Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Crisaborole ointment 2%
Drug: Vehicle

First Posted Date: 2019-05-17

Last Posted Date: 2020-07-14

Lead Sponsor: Pfizer

Target Recruit Count: 81

Registration Number: NCT03954158

Locations: 🇯🇵
Fukuwa Clinic, Chuo-ku, Tokyo, Japan
🇯🇵
Sekino Hospital, Toshima-ku, Tokyo, Japan
🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

Phase 3

Active, not recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Etrasimod

First Posted Date: 2019-05-15

Last Posted Date: 2024-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 778

Registration Number: NCT03950232

Locations: 🇧🇪
AZ Delta Roeselare VZW Campus, Roeselare, Belgium
🇫🇷
CHU Nantes - Hôtel Dieu, Nantes, France
🇩🇪
Krankenhaus Waldfriede e.V.,, Berlin, Germany

and more 666 locations

Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options

Conditions: Sickle Cell Disease

First Posted Date: 2019-05-09

Last Posted Date: 2023-07-18

Lead Sponsor: Pfizer

Registration Number: NCT03943615

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸
The John Hopkins Hospital, Baltimore, Maryland, United States

and more 15 locations

Trial for Treatment Refractory Trigeminal Neuralgia

Phase 2

Terminated

Conditions: Trigeminal Neuralgia

Interventions: Drug: Rimegepant
Drug: Placebo

First Posted Date: 2019-05-08

Last Posted Date: 2024-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 65

Registration Number: NCT03941834

Locations: 🇺🇸
Center for Neurohealth DBA Kaizen Brain Center, La Jolla, California, United States
🇺🇸
Imaging Clinic at Stanford Neuroscience Health Center, Palo Alto, California, United States
🇺🇸
Stanford Neuroscience Health Center- SNHC Pharmacy, Palo Alto, California, United States

and more 16 locations

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Phase 3

Active, not recruiting

Conditions: Hemophilia B
Hemophilia A

Interventions: Drug: PF-06741086

First Posted Date: 2019-05-06

Last Posted Date: 2024-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 186

Registration Number: NCT03938792

Locations: 🇺🇸
Washington Institute for Coagulation, Seattle, Washington, United States
🇨🇳
Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇺🇸
USF Health Morsani Center For Advanced Healthcare, Tampa, Florida, United States

and more 61 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy